This project will compare the amount of bile acids and their kinetics in overweight and obese
people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes.
We hypothesize that bile acids will behave differently in these groups. We will also explore
the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids,
on bile acids in those groups. We hypothesize the drug may have different actions on bile
acids in subjects with different degrees of abnormal glucose metabolism.
Details
Lead Sponsor:
KineMed
Collaborators:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc. Diabetes & Glandular Disease Research Associates University Medical Center Groningen